Enhances insulin sensitivity, improving glucose metabolism Suppresses appetite and reduces food cravings, aiding in lower calorie intake Slows gastric emptying, prolonging satiety and reducing overeating Promotes significant weight loss, even in individuals with obesity-related conditions Typical Dosage: Start with 2.5 mg once weekly, gradually 515 mg depending on patient response and tolerance Administration: Subcutaneous injection, typically in the abdomen, thigh, or upper arm Side Effects Nausea and vomiting Fatigue and mild dizziness Gastrointestinal issues Possible hypoglycemia when combined with other diabetes medications Injection site reactions, redness or irritation 3
On day 21, mice were anesthetized by intraperitoneal injection of 2.5% tribromoethanol followed by retro-orbital blood collection, euthanasia via cervical dislocation, and heart tissue harvest and weighing
Key point: 32% vs 17% symptom improvement over 1 year for GLP-1 users vs non-users
NAD+ precursors are studied for supplying metabolic substrates
The differences in measurements of blood glucose, insulin and body weight across most time points were not statistically significantly different, with remarkable similarity in many areas and slight differences in others
That post-start experience often matters more than the difference in monthly price
